Intravitreal Bevacizumab

Phase 3Monoclonal antibody

AAsociación para Evitar la Ceguera en México

Intravitreal Bevacizumab is one of 169 small molecule programs targeting Choroidal Neovascularization. It is currently in Phase 3.

Indications

Total Trials

Active Trials

168

Competitors

Pipeline

Status by Indication[3][1]

Indication

Choroidal NeovascularizationActive, not recruiting

Proliferative Diabetic RetinopathyActive, not recruiting

HemorrhageActive, not recruiting

Macular DegenerationActive, not recruiting

Retinopathy of PrematurityActive, not recruiting

Polypoidal Choroidal VasculopathyActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Choroidal NeovascularizationPhase 3

Active, not recruiting

Proliferative Diabetic RetinopathyPhase 2

Active, not recruiting

HemorrhagePreclinical

Active, not recruiting

Macular DegenerationPhase 2/Phase 3

Active, not recruiting

Retinopathy of PrematurityPhase 3

Active, not recruiting

Polypoidal Choroidal VasculopathyPreclinical

Active, not recruiting

Diabetic Macular EdemaPhase 3

Active, not recruiting

Diabetic RetinopathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

180 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

59 2

Eylea

Regeneron

Phase 3

54 3

Avastin

BBio-Thera Solutions

Phase 3

23 4

Beovu

Novartis

Phase 3

6 5

Kenalog

BBausch Health Americas, Inc.

Phase 3

14 6

Synalar

EEurofarma Laboratorios S.A.

Phase 3

4 7

Lucentis

Novartis

Phase 3

8 8

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

3 9

Intravitreal Ranibizumab

Roche

Phase 3

4 10

Glucophage

EMD Serono

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Macular Edema8 trials

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Completed·AAsociación para Evitar la Ceguera en México·Phase 4·NCT05736081·15 enrolled

Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema

Unknown status·IInje University·Phase 4·NCT02399657·48 enrolled

Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Completed·TTehran University of Medical Sciences·Phase 2·NCT02663141·57 enrolled

Show 5 more trials

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Withdrawn·AAsociación para Evitar la Ceguera en México·Phase 3·NCT00417716

Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

Completed·UUniversity of Sao Paulo·Phase 3·NCT02308644·41 enrolled

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated·—·Phase 4·NCT04991350·5 enrolled

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Completed·RRetina Macula Institute·Phase 2·NCT01571232·20 enrolled

Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)

Completed·UUniversity of Sao Paulo·Phase 3·NCT00997191·12 enrolled

Proliferative Diabetic Retinopathy2 trials

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Completed·AAnders Kvanta·Phase 2·NCT01478737·100 enrolled

Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Completed·JJ. Fernando Arevalo, MD FACS·Phase 3·NCT01976923·224 enrolled

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT03609307·40 enrolled

5 more indications

ESS1 trial

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Unknown status·UUniversity of Malaya·N/A·NCT01626339·30 enrolled

Bevacizumab1 trial

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Terminated·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00417833

Retinopathy of Prematurity1 trial

A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

Completed·—·Phase 3·NCT05712642·19 enrolled

Hemorrhage1 trial

Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation

Unknown status·NNational Taiwan University Hospital·N/A·NCT00673296·6 enrolled

Polypoidal choroidal vasculopathy1 trial

Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Unknown status·—·N/A·NCT00383812·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Intravitreal Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asociación para Evitar la Ceguera en México company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAsociación para Evitar la Ceguera en México

Intravitreal Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Macular Edema8 trials

Proliferative Diabetic Retinopathy2 trials

Choroidal Neovascularization1 trial

Diabetic Retinopathy1 trial

Macular Degeneration1 trial

ESS1 trial

Bevacizumab1 trial

Retinopathy of Prematurity1 trial

Hemorrhage1 trial

Polypoidal choroidal vasculopathy1 trial

References

Drug Info

Quick Facts

Related News